Home > Neurology > Plasma P-tau217 emerging as biomarker of early AD

Plasma P-tau217 emerging as biomarker of early AD


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Neurology
Reuters Health - 11/11/2020 - Researchers are honing in on the best blood biomarker to detect Alzheimer disease (AD) at its earliest stages and plasma tau phosphorylated at threonine 217 (P-tau217) is a front runner. According to a new study in JAMA Neurology, blood levels of P-tau217 are increased in early preclinical AD, and the change happens before tau pathology is detected on positron emission tomography (tau-PET). Dr. Shorena Janelidze of Lund University and colleagues compared changes in blood P-tau217 levels in preclinical and prodromal AD relative to changes in cerebrospinal fluid (CSF) P-tau217 and PET measures in 314 cognitively normal older adults and 176 with mild cognitive impairment (MCI) participating in the Swedish BioFINDER-2 study. Blood levels of P-tau217 were elevated in amyloid-positive, cognitively unimpaired older adults before tau aggregates became detectable by tau-PET, the researchers report. In cognitively normal adults and ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on